{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:43:46Z","timestamp":1787028226650,"version":"build-2736575974"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JIPMER intramural research grant  &amp; CANSEARCH Foundation","award":["JIP\/Res\/PhDRMC\/26\/2014 & CANSEARCH"],"award-info":[{"award-number":["JIP\/Res\/PhDRMC\/26\/2014 & CANSEARCH"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Genetic variants influencing the pharmacokinetics and\/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explored the association of candidate genetic variants with early hematological TRT (grade 3\u20134) occurring within the first 100 days of low-dose methotrexate and 6-mercaptopurine based maintenance therapy (n = 73). Fourteen variants in the following candidate genes were genotyped using allele discrimination assay by real-time PCR: ABCB1, DHFR, GGH, FPGS, MTHFR, RFC1, SLCO1B1, TPMT, and NUDT15. Methotrexate polyglutamate (MTXPG3-5) levels in red blood cells were measured by LC-MS\/MS. Early hematological TRT (grade 3\u20134) was seen in 54.9% of patients. The NUDT15c.415T allele was associated with early TRT occurrence [HR: 3.04 (95% CI: 1.5\u20136.1); p = 0.007]. Sensitivity of early TRT prediction improved (from 30.7% to 89.7%) by considering FPGS variant (rs1544105\u2019T\u2019) carrier status along with NUDT15c.415T allele [HR = 2.7 (1.5\u20134.7, p = 0.008)]. None of the considered genetic variants were associated with MTXPG3-5 levels, which in turn were not associated with early TRT. NUDT15c.415T allele carrier status could be used as a stratifying marker for Indian ALL patients to distinguish patients at high or low risk of developing early hematological TRT.<\/jats:p>","DOI":"10.3390\/genes11060594","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:44:02Z","timestamp":1590713042000},"page":"594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Association of NUDT15 c.415C&gt;T and FPGS 2572C&gt;T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-5985","authenticated-orcid":false,"given":"Sunitha","family":"Kodidela","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Tennessee Heath Science Center, Memphis, TN 38163, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patchava","family":"Dorababu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Apollo Institute of Medical Sciences and Research, Hyderabad 500090, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpal N.","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education &amp; Research, Pondicherry 605006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education &amp; Research, Pondicherry 605006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education &amp; Research, Pondicherry 605006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha","family":"Muralidharan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education &amp; Research, Pondicherry 605006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Prasad","family":"Nidanapu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education &amp; Research, Pondicherry 605006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Aribandi","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology, Care Hospitals, Hyderabad 500019, India"},{"name":"American Oncology Institute, Nallagandla Serilingampalli, Hyderabad 500019, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Chandra","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakradhara Rao Satyanarayana","family":"Uppugunduri","sequence":"additional","affiliation":[{"name":"Onco-Hematology Unit, Research Platform of Pediatric Onco-Hematology, Department of Paediatrics, Gynaecology and Obstetrics, University Hospitals of Geneva, University of Geneva, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/sajc.sajc_13_18","article-title":"Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia","volume":"7","author":"Chennamaneni","year":"2018","journal-title":"South Asian J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/MPH.0b013e31820e7361","article-title":"Survival outcome of childhood acute lymphoblastic leukemia in India: A resource-limited perspective of more than 40 years","volume":"33","author":"Kulkarni","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/2278-330X.187590","article-title":"Acute childhood leukemia in India: Where are we going, where have we been?","volume":"5","author":"Kanwar","year":"2016","journal-title":"South Asian J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/1735-1995.178754","article-title":"Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience","volume":"21","author":"Kapoor","year":"2016","journal-title":"J. Res. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/2278-330X.187591","article-title":"Acute leukemia in children: A review of the current Indian data","volume":"5","author":"Arora","year":"2016","journal-title":"South Asian J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00228-015-1930-z","article-title":"Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia","volume":"71","author":"Kodidela","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0306-3623(99)00022-1","article-title":"The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX)","volume":"33","author":"Giverhaug","year":"1999","journal-title":"Gen. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0021-9258(17)43612-X","article-title":"Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin","volume":"259","author":"Lewis","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/clpt.1987.45","article-title":"The effect of methotrexate on the bioavailability of oral 6-mercaptopurine","volume":"41","author":"Balis","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Joint Bone Spine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2119\/molmed.2011.00048","article-title":"Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo","volume":"18","author":"Wang","year":"2012","journal-title":"Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002800050405","article-title":"Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate","volume":"37","author":"Innocenti","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10928-014-9355-3","article-title":"Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate","volume":"41","author":"Ogungbenro","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ejca.2004.11.004","article-title":"Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]","volume":"41","author":"Magrath","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","article-title":"Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia","volume":"93","author":"Relling","year":"1999","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00228-011-1133-1","article-title":"Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia","volume":"68","author":"Dorababu","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-013-1623-4","article-title":"Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: Why still at the bench level?","volume":"70","author":"Kodidela","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-018-3732-3","article-title":"Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia","volume":"83","author":"Khera","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2867-13-107","article-title":"FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"13","author":"Liu","year":"2013","journal-title":"Cancer Cell Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0000000000000282","article-title":"The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia","volume":"27","author":"Moriyama","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","article-title":"Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia","volume":"33","author":"Yang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fphar.2019.00916","article-title":"ITPA, TPMT, and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia","volume":"10","author":"Moradveisi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00556900","article-title":"Pharmacokinetics of methotrexate in erythrocytes in psoriasis","volume":"27","author":"Hendel","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","first-page":"190","article-title":"Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment","volume":"16","author":"Clausen","year":"1986","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1002\/rcm.4300","article-title":"A novel high-performance liquid chromatography\/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells","volume":"23","author":"Becker","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann. Statist."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/tpj.2017.12","article-title":"Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia","volume":"18","author":"Tanaka","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4143\/crt.2017.283","article-title":"NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia","volume":"50","author":"Yi","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhou, H., Li, L., Yang, P., Yang, L., Zheng, J.E., Zhou, Y., and Han, Y. (2018). Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4398-2"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/cpt.1268","article-title":"Pharmacogene Variation Consortium Gene Introduction: NUDT15","volume":"105","author":"Yang","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","unstructured":"(2020, May 27). PharmVar. Available online: https:\/\/www.pharmvar.org\/gene\/NUDT15."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/ped.13905","article-title":"Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia","volume":"61","author":"Buaboonnam","year":"2019","journal-title":"Pediatr. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1373\/clinchem.2005.050831","article-title":"Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine\/6-mercaptopurine therapy","volume":"51","author":"Dervieux","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gut.39.3.401","article-title":"6-Mercaptopurine metabolism in Crohn\u2019s disease: Correlation with efficacy and toxicity","volume":"39","author":"Cuffari","year":"1996","journal-title":"Gut"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ibd.21458","article-title":"Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease","volume":"17","author":"Haines","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Muralidharan, N., Sundaram, R., Kodidela, S., Chengappa, K.G., Mariaselvam, C.M., Misra, D.P., and Negi, V.S. (2019). Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients. Pharmacogenomics J., 1\u20138.","DOI":"10.1038\/s41397-019-0097-x"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-013-0052-y","article-title":"A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells","volume":"52","author":"Korell","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"35615","DOI":"10.1038\/srep35615","article-title":"Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis","volume":"6","author":"Yamamoto","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Panetta, J.C., Sparreboom, A., Pui, C.-H., Relling, M.V., and Evans, W.E. (2010). Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput. Biol., 6.","DOI":"10.1371\/journal.pcbi.1001019"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/ijmpo.ijmpo_32_17","article-title":"Interethnic differences in single and haplotype structures of folylpolyglutamate synthase and gamma-glutamyl hydrolase variants and their influence on disease susceptibility to acute lymphoblastic leukemia in the Indian population: An exploratory study","volume":"39","author":"Kodidela","year":"2018","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","article-title":"LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants","volume":"31","author":"Machiela","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Fagerberg","year":"2015","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.3390\/nu5114333","article-title":"The need for evidence based nutritional guidelines for pediatric acute lymphoblastic leukemia patients: Acute and long-term following treatment","volume":"5","author":"Owens","year":"2013","journal-title":"Nutrients"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2013.52.6962","article-title":"Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group","volume":"32","author":"Orgel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPH.0b013e3181d7ae0d","article-title":"Pattern of relapse in childhood ALL: Challenges and lessons from a uniform treatment protocol","volume":"32","author":"Arya","year":"2010","journal-title":"J. Pediatr. Hematol. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/6\/594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:33:19Z","timestamp":1760175199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/6\/594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["genes11060594"],"URL":"https:\/\/doi.org\/10.3390\/genes11060594","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]}}}